ERNA Ernexa Therapeutics Inc.
$4.17▲ +3.61%
Healthcare
Other
After hours
$4.14▼ -0.53%
Sep 11, 4:39 PM ET
Volume 19.6K
Avg Volume (10D) 21.5K
Key Metrics & Fundamentals
Market Cap
$4.86M
P/E Ratio
0.0
Div Yield
–%
52W Range
3.18 - 71.50
% vs 50 MA
-11.75%
% vs 200 MA
-66.56%
RSI-14
42.9
MACD Histogram
-0.0300
Beta (1Y vs SPY)
0.74
Free Cash Flow
-$4.16M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.10M
COGS
–
Operating Exp
$4.10M
Operating Income
-$4.10M
EBIT
-$4.10M
Pretax Income
-$4.01M
Net Income
-$4.01M
EPS (Diluted)
-3.40
Price & Volume History
Loading chart…
Recent News
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire · Aug 27, 2026 1:01 PM
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
GlobeNewswire · Jul 24, 2026 1:20 PM
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
InvestorsHub · Jul 15, 2026 1:43 PM
Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination
MT Newswires · Jul 15, 2026 1:01 PM
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
GlobeNewswire · Jul 15, 2026 11:50 AM
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
GlobeNewswire · Jul 14, 2026 1:01 PM
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
GlobeNewswire · Jun 25, 2026 1:15 PM
Ernexa Therapeutics Says Investigational New Drug Submission for ERNA-101 on Track for Q3
MT Newswires · Jun 17, 2026 1:19 PM
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
GlobeNewswire · Jun 17, 2026 12:47 PM
Financial Overview - Income Statement
Quarterly
Dec 2024
See ERNA's money flow as a full page
Social Sentiment
No Reddit posts found for ERNA.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.